Uncategorized
VIDEO: Aerie CEO reviews company’s recent advances in glaucoma
CHICAGO — At the Ophthalmology Innovation Summit here, chairman and chief executive officer of Aerie Pharmaceuticals Vincente Anido Jr., PhD, says "spectacular" progress has been made with regard to two of the company's leading glaucoma products. In September, the company filed a new drug application for Rhopressa (netarsudil), a rho kinase inhibitor that acts on the trabecular meshwork, and "very successful" phase 3 trial results were reported for Roclatan, a product combining Rhopressa and latanoprost.